Background {#Sec1}
==========

Ovarian cancer (OC) is the fourth most common cause of cancer-related deaths in women, with an estimated 200,000 cases and 125,000 deaths occurring annually worldwide \[[@CR1], [@CR2]\]. Despite current advances in surgery and adjuvant chemotherapy, the clinical outcome of patients with OC remains uncertain, with the 5-year survival rate being \~30% for advanced-stage disease. The poor survival rate is largely attributed to the poor understanding of the OC initiation and progression \[[@CR3]\]. The discovery of novel biomarkers with high sensitivity and specificity for the early diagnosis and target therapies of OC will help to improve the prognosis of this disease.

Epigenetic changes, such as DNA methylation and histone post-translational modifications, are major contributing factors for carcinogenesis \[[@CR4]\]. Given that epigenetic changes are reversible, there is a hope that reversing epigenetic malfunction in cancer cells could render them normal, launching a new and rapidly expanding field of cancer epigenetic therapeutics \[[@CR5]\]. Disruptor of telomeric silencing-1-like (DOT1L), a human homologue of DOT1 in yeast, is the only histone methyltransferase that produces methylated H3K79 (H3K79me~*x*~, *x* = 1, 2, or 3). Globally, H3K79 methylation is enriched in actively transcribing genes \[[@CR6]\]. In addition to transcription, Dot1 plays an important role in cell cycle regulation and the DNA damage response \[[@CR7]\]. Recent studies have revealed that DOT1L is involved in the initiation and maintenance of mixed lineage leukemia (MLL)-rearranged leukemia, by associating with MLL fusion partner proteins, e.g., AF4, AF9, AF10, or ENL, resulting in abnormal H3K79 methylation and overexpression of a number of MLL target genes (e.g., HoxA9 and Meis1) \[[@CR8]--[@CR10]\]. Consequently, DOT1L is a drug target for MLL-rearranged leukemia \[[@CR11], [@CR12]\]. Furthermore, a few recent publications have reported that DOT1L plays crucial roles not only in leukemia, but also in solid tumors, such as breast cancer, esophageal squamous cell carcinoma, colorectal cancer, prostate cancer, and gastric cancer \[[@CR13]--[@CR19]\]. Moreover, DOT1L inhibitors have shown effective suppression of proliferation, migration, and invasion of breast cancer \[[@CR20]\].

To date, the potential role of DOT1L and its malignancies in OC have not been assessed. In this study, the prognostic significance of DOT1L expression in OC for clinicopathological parameters and patient survival was evaluated. Moreover, it is very significant that we identified DOT1L as a promising therapeutic target for OC both in vitro and in vivo experiments.

Methods {#Sec2}
=======

Patients and samples {#Sec3}
--------------------

A total of 274 formalin-fixed paraffin-embedded tissue samples were included in this study, comprising 24 normal ovarian tissues, 15 benign ovarian tumor, 7 borderline ovarian tumor, and 228 malignant ovarian tumor samples. These samples were obtained from patients diagnosed with ovarian carcinoma who underwent intitial surgery at the Gynecology Department of Huazhong University of Science and Technology Affiliated Tongji Hospital from 2003 to 2013. The tissue samples were obtained with informed consent from patients. None of the patients had any prior history of chemoradiation, radiation, or hormonal therapy before the surgery. Clinical information of the patients' was recorder in detail, and the diagnoses were confirmed by at least two pathologists. The histopathologic subtypes of the 7 borderline ovarian tumor and 228 malignant ovarian tumor samples included 211 serous cystadenocarcinomas, 5 mucinous cystadenocarcinomas, 12 endometrioid adenocarcinomas, 4 ovarian germ-cell tumors, 2 ovarian clear-cell carcinomas, and 1 ovarian transitional cell carcinoma. There were 20 cases in stage I, 17 cases in stage II, 159 cases in stage III, 29 cases in stage IV, and 10 cases remained unknown, according to the International Federation of Gynecology and Obstetrics (FIGO) staging system. With regard to histological grading, 40 cases had grade 1, 58 cases had grade 2, 120 cases had grade 3, and 17 cases remained unknown. The median age of patients (16--80 years old) was 54 years old. Among the 235 OC tissues, the total of 206 cases has been followed up. The present study was with the approval and support of the Ethics or Institutional Review Board of Tongji Hospital.

Immunohistochemistry {#Sec4}
--------------------

Formalin-fixed, paraffin-embedded tissue blocks were retrieved from the archive and were analyzed by IHC described previously \[[@CR21]\]. In short, The Avidin-Biotin Complex (ABC) Vectastain Kit (Zsgb-Bio, Beijing, China) was used and the DOT1L polyclonal antibody (1:250; ab64077; Abcam), H3K79me2 polyclonal antibody (1:200; ab3594; Abcam), cyclin D3 antibody (1:100; ab63535; Abcam), and the CDK6 polyclonal antibody (1:500; GTX103992; GeneTex) were used as primary antibodies incubated with tissue sections (2 mm) after heat-induced epitope retrieval (10 mM sodium citrate buffer of pH 6.0), followed by incubation with a secondary antibody conjugated to peroxidase (1:100; Dako). Detection was performed using diaminobenzidine for 8 min, and the slides were counterstained with hematoxylin.

The scoring system that was used incorporated both the intensity of the scoring (0 = absent, 1 = weak, 2 = moderate, 3 = strong) and the percentage of positive tumor cells (0 = 0%, 1 = 1--25%, 2 = 26--50%, 3 = 51--75%, 4 = 76--100%). Points for the intensity and the percentage of staining were added and assigned as overall score according to Kamat and M. Caroline \[[@CR22], [@CR23]\]. Two investigators scored all slides for DOT1L and H3K79 methylation staining and followed the criterions of double-blind trials. Based on the overall score, the DOT1L and H3K79 methylation staining results were classified into low expression (≤4) and high expression (\>4).

Cells and transfection {#Sec5}
----------------------

Human epithelial ovarian cell lines SK-OV-3, TOV21G, OV90, and CaOV3 were purchased from the American Type Culture Collection (Manassas, VA, USA). SK-OV-3 and CaOV3 were cultured in McCoy's 5A Medium (Boster, Wuhan, China), while TOV21G and OV90 in mixed MCDB105 Medium (Sigma-Aldrich Co., St Louis, MO, USA) and M199 Medium (Gibco, Invitrogen, Carlsbad, CA, USA) (1:1) supplemented with 10% fetal bovine serum (Gibco, Invitrogen, Carlsbad, CA, USA) and 1% penicillin/streptomycin at 37 °C in a humidified atmosphere of 5% CO~2~ and 95% air. The cells were transduced with CMV-Fluc-IRES-RFP lentiviral particles (GeneChem, Shanghai, China). RFP/luciferase-expressing cells were isolated by FACS and used in living imaging. ShDOT1L-1 and shDOT1L-2 shRNA lentiviral particles (GeneChem) were used to knock-down DOT1L expression, targeting 5′-CGGATCTCAAGCTCGCTAT-3′ and 5′-AGTGCTCGAATTGAGAGAA-3′, respectively. ShCON, the short hairpin RNA (shRNA) not targeting any known gene, was used as control. SK-OV-3 and TOV21G cells were transduced with DOT1L shRNA lentiviral particles, or control shRNA lentiviral particles. The cells with stable transfection were selected with puromycin.

Assay of gene expression by real-time RT-PCR {#Sec6}
--------------------------------------------

Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA). RT-PCR analysis was carried out in a CFX96 Touch™ Real-Time PCR Detection system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and iQ™ SYBR®Green Supermix (Bio‑Rad Laboratories, Inc., Hercules, CA, USA), which contained 5 ng complementary DNA (cDNA) and 10 pM of each primer. The primer sequences used for PCR are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1. The relative messenger RNA (mRNA expression) levels were normalized to that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The PCR protocol is as follows: denaturation at 95 °C for 10 min; 40 cycles of denaturation at 95 °C for 10 sec; annealing at 60 °C for 30 sec; and extension at 72 °C for 30 sec. Each sample was assayed in triplicate, and relative mRNA expression levels were calculated using the △△Ct method.

Western blot analysis {#Sec7}
---------------------

Western blot assay was performed following the protocol as previously described \[[@CR24], [@CR25]\]. Briefly, the cells were harvested and lysed using ice-cold RIPA lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM sodium chloride, 1% Nonidet P-40, and 0.5% sodium deoxycholate). Following centrifugation at 10,000×*g* for 15 min at 4 °C, the proteins in the supernatants were quantified by Bradford method and separated using 10% SDS-PAGE gel and electrotransferred from the gel to a nitrocellulose membrane (Merck & Co., Inc., Whitehouse Station, NJ, USA). Following blocking with 5% skimmed milk in phosphate-buffered saline, the membranes were immunoblotted with the primary antibodies, namely, CDK6 (GeneTex, San Antonio, Texas, USA), DOT1L, H3, H3K79me2, cyclin D3, and GAPDH (Abcam, Cambridge, UK) at 4 °C overnight. Specifically bound HRP-conjugated secondary antibodies were detected using an ECL detection system (ChemiDocTM XRS+ machine, Bio-Rad Laboratories). Protein levels of GAPDH and H3 were employed as loading controls. Densitometric analyses were performed using ImageJ software. Relative quantification was carried out after normalization to the band intensities of GAPDH or H3. A Mann-Whitney test was performed to assess the difference of protein expression between groups. Each experiment was performed in triplicate and repeated at least 3 times.

In vitro cell viability {#Sec8}
-----------------------

Cell proliferation was evaluated using a colorimetric assay as described previously \[[@CR26]\]. Cell viability was measured by a commercially Cell Counting Kit (CCK-8, Beyotime Institute of Biotechnology, China). The indicated cells were seeded into 96-well plates at a density of 10^4^ cells per well. The drugs were added when the plates were seeded. After incubation for 3, 6, 9, and 12 days, cell proliferation in 96-well plates was measured and 10 μL CCK-8 reagent was added to each well and incubated at 37 °C for 4 h. Absorbance was measured at 450 nm by using a spectrophotometer. Each experiment was performed in triplicate and repeated at least 3 times.

Colony formation assay {#Sec9}
----------------------

The colony formation assay was performed on the indicated cells. For each group, 800 survived cells/well were incubated in 6-well plates, containing 2.5 ml complete medium per well, followed by incubation for 10 days. At the indicated time point, cells were washed twice with PBS, treated with crystal violet for 10 min, washed, then counted, and measured. All the experiments were performed at least 3 times. The colonies with \>40 cells were subsequently counted under a phase contrast microscope at ×40 magnification.

### Cell cycle and cell apoptosis analyses {#Sec10}

Cell cycle and cell apoptosis analyses were determined by flow cytometry (BD, UA) \[[@CR27], [@CR28]\]. In this experiment, the SK-OV-3 and TOV21G cells were treated with 10 μM SGC0946 and EPZ004777 for 12 days, respectively. Then, the cells treated above were harvested and washed with phosphate-buffered saline (PBS). For cell cycle analysis, the pellets were fixed with ice-cold 70% ethanol overnight at 4 °C. Cell pellets were then suspended in 300 μl PBS containing 100 μg/ml RNase for 30 min at room temperature, and then 10 μg/ml propidium iodide (Sigma-Aldrich Co., St Louis, MO, USA). The distribution of cells in the different phases of the cell cycle was analyzed from DNA histograms using BD Cell Quest software (Becton Dickinson Biosciences, San Diego, CA, USA). For cell apoptosis analysis, cells were resuspended in 500 μl binding buffer (Annexin V-FITC/PI Apoptosis Detection Kit (BD Biosciences)), containing 5 μl of annexin V-fluorescein isothiocyanate (FITC) stock and 5 μl of 20 μg/ml PI for determination of phosphatidylserine (PS) exposure on the outer plasma membrane. After incubation for 10 min at room temperature in a light-protected area, the cells were quantified by flow cytometry. Viable cells were annexin V- and PI-negative.

### ChIP-qPCR and ChIP-Seq {#Sec11}

ChIP assays were performed following the protocols as previously described \[[@CR13], [@CR29], [@CR30]\]. In brief, crosslinking was performed with 1% formaldehyde at room temperature for 10 min and the reaction was stopped by treatment with 0.125 M glycine. The cell pellets were resuspended in 200 ml of SDS lysis buffer and sonicated using a Bioruptor (Cosmo Bio Co. Ltd, Tokyo, Japan). The cell lysates were then immunoprecipitated with specific antibodies overnight at 4 °C and further incubated with salmon sperm DNA coupled to protein A-agarose (Millipore) for 2 h at 4 °C. The precipitates were washed, eluted, and then reverse-crosslinked with 20 ml 5 M NaCl by incubating at 65 °C overnight. DNA fragments were precipitated from the eluate and dissolved in ddH~2~O. Eluted DNA fragments were analyzed by qPCR, or subjected to sequencing using next-generation Solexa sequencing.

Animal studies {#Sec12}
--------------

Female NOD-SCID mice (4 weeks old) were purchased from Beijing HFK Bio-Technology Co. Ltd. (Beijing, China). The studies were approved by the Committee on Ethics of Animal Experiments of Tongji Medical College. The mice were maintained in the accredited animal facility of Tongji Medical College. Upon injection of SK-OV-3 cells transduced with CMV-Fluc-IRES-RFP lentiviral particles into the ovarian bursa bilaterally of female mice, we have developed an orthotopic ovarian tumor model. SGC0946 (10 mg/kg per mouse) was administered intraperitoneal twice a week for 6 weeks. The size of tumor was monitored in living mice by optical imaging of luciferase activity using the IVIS Spectrum system (Caliper, Xenogen, USA). After anaesthetization with 3% pentobarbital sodium, mice were imaged 10 min after intraperitoneal injection of 100 mg/kg D-luciferin. In the experimental metastasis model \[[@CR31], [@CR32]\], tumor cells were injected into mice via the tail vein (2 × 10^6^ cells/mouse). At each time option, mice were monitored using the IVIS SPECTRUM system according to the method above. Total flux (photons/s) was quantified using Living Image version 4.3.1 software.

Statistical analysis {#Sec13}
--------------------

Chi-squared tests were used to evaluate whether DOT1L expression was correlated with clinicopathological factors of OC. Overall survival (OS) and progression-free survival (PFS) curves were plotted using the Kaplan-Meier analysis followed by two-sided log-rank tests. The univariate and multivariate Cox proportional hazards modeling was used to evaluate prognostic significance. For cell-based assays, differences between groups were assessed by two sided Student's *t* tests, unless indicated otherwise. Data were analyzed using SPSS 18.0 statistic software (SPSS Inc., Chicago, IL). Each experiment was repeated at least 3 times with comparable results, unless indicated otherwise. Significance was assessed at the level of *P* \< 0.05. (\**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001).

Results {#Sec14}
=======

DOT1L and H3K79 methylation expression in normal ovarian tissues and benign, borderline, and malignant ovarian tumors {#Sec15}
---------------------------------------------------------------------------------------------------------------------

Immunohistochemical staining for DOT1L (Fig. [1a](#Fig1){ref-type="fig"}) and H3K79 methylation (Additional file [2](#MOESM2){ref-type="media"}: Figure S1a) expression was performed on 24 normal ovarian tissues, 15 benign ovarian tumors, 7 borderline ovarian tumors, and 228 malignant ovarian tumors. At the time of analysis, 94 (45.6%) of the 206 evaluable patients had died and 131 (63.6%) of the 206 evaluable patients had experienced disease progression, resulting in a median OS of 36 months (95% CI, 24.5 to 47.5 months) and median PFS of 30 months (95% CI, 25.1 to 34.9 months). The average length of follow-up time for the 112 patients still alive was 38.5 months (range, 10 to 81 months). The percentage of high DOT1L expression was 14.6% in normal ovarian tissues, 23.4% in benign ovarian tumors, 21.5% in borderline ovarian tumors, and increased to 57.5% in malignant ovarian tumors (normal vs. malignant, *P* \< 0.0001; benign vs. malignant, *P* = 0.012; borderline vs. malignant, *P* = 0.082; normal vs. benign, *P* = 0.69; normal vs. borderline, *P* = 0.62; benign vs. borderline, *P* = 1.00) (Fig. [1b](#Fig1){ref-type="fig"}). Similarly, H3K79 methylation was significantly increased in malignant ovarian cancer with 59.3% of high H3K79 methylation, while normal ovarian tissues with 16.65%, benign ovarian tumors with 16.65%, and borderline ovarian tumors with 37.75% (normal or benign vs. malignant, *P* \< 0.0001; borderline vs. malignant, *P* = 0.0045; normal or benign vs. borderline, *P* = 0.0014) (Additional file [2](#MOESM2){ref-type="media"}: Figure S1b).Fig. 1DOT1L protein expression in human ovarian tissues and Kaplan-Meier plots. **a** Immunohistochemical staining of DOT1L protein in human ovarian tissues. A *brown color* in cancer cells is considered as a positive staining. Negative control without first antibody is performed in the normal ovarian tissue. Representative images of DOT1L expression in normal ovarian tissues and benign, borderline, and malignant ovarian tumors are shown. Original magnification ×100 and ×400. *Scale bar* 100 and 25 μm, respectively. **b** The case rate of DOT1L high and low expression. For comparison between two groups, *χ* ^2^ test was applied. **c** Overall survival (OS) rate in patients with high DOT1L expression was significantly lower than in patients with no or low DOT1L expression. **d** Progression-free survival (PFS) rate in patients with high DOT1L expression was significantly lower than in patients with no or low DOT1L expression

Association between DOT1L expression and clinicopathological parameters of OC {#Sec16}
-----------------------------------------------------------------------------

To clarify the potential prognostic roles of DOT1L in OC development and progression, we evaluated the association of DOT1L expression with various clinical features of 235 cases of OC, including 7 borderline ovarian tumors and 228 malignant ovarian tumors (Table [1](#Tab1){ref-type="table"}). High expression of DOT1L was associated with FIGO stage (*P* = 0.001), histologic grade (*P* = 0.012), and lymph node metastasis (*P* = 0.036). However, there was no significant association between DOT1L expression and patients' age (*P* = 0.729), ascites (*P* = 0.944), and level of preoperative CA125 (*P* = 0.176) (Table [1](#Tab1){ref-type="table"}).Table 1Association of DOT1L expression with the clinicopathological features of patients with borderline and malignant ovarian tumorsCharacteristicsSampleDOT1L expression*χ* ^2^*P*Low expressionHigh expressionAge at diagnosis2350.1200.729 ≤5011451 (44.7%)63 (55.3%) \>5011755 (47.0%)62 (53.0%) Unknown4FIGO stage23517.6550.001 I2018 (90.0%)2 (10.0%) II178 (47.1%)9 (52.9%) III15966 (41.5%)93 (58.5%) IV2911 (37.9%)18 (62.1%) Unknown10Histologic grade2358.8310.012 Grade 14027 (67.5%)13 (32.5%) Grade 25824 (41.4%)34 (58.6%) Grade 312050 (41.7%)70 (58.3%) Unknown17Ascites2350.0050.944 Yes17378 (45.1%)95 (54.9%) No3616 (44.4%)20 (55.6%) Unknown26LN metastasis2354.3920.036 Yes7329 (39.7%)44 (60.3%) No10659 (55.7%)47 (44.3%) Unknown56Preoperative CA125 (U/ml)2351.8290.176 ≤6006833 (48.5%)35 (51.5%) \>6008030 (37.5%)50 (62.5%) Unknown87

High expression of DOT1L as an independent prognostic marker of OC {#Sec17}
------------------------------------------------------------------

We used only 228 malignant ovarian tumor samples for survival analysis. The Kaplan-Meier survival analysis indicated that OC patients with high expression of DOT1L exhibited a significantly reduced OS (*P* \< 0.001, Fig. [1c](#Fig1){ref-type="fig"}) and PFS (*P* \< 0.001, Fig. [1d](#Fig1){ref-type="fig"}) than those with low expression. In addition, we determined prognostic factors of OS and PFS using the univariate (Additional file [3](#MOESM3){ref-type="media"}: Table S2) and multivariate (Table [2](#Tab2){ref-type="table"}) Cox regression model. The results identified high expression of DOT1L (*P* \< 0.001), and age (*P* = 0.002) as prognostic factors of OS independent of other clinicopathological factors (Table [2](#Tab2){ref-type="table"}). Meanwhile, the results identified high expression of DOT1L (*P* \< 0.001), age (*P* = 0.005), and level of preoperative CA125 (*P* \< 0.001) as prognostic factors of PFS independent of other clinicopathological factors (Table [2](#Tab2){ref-type="table"}). Taken together, these results suggest that DOT1L expression was significantly increased in malignant ovarian tumors. Higher DOT1L expression was associated with advanced FIGO stage, poor histopathological grade, and lymph node metastasis of OC patients. Importantly, DOT1L expression was identified as an independent prognostic factor for OC.Table 2Multivariate Cox regression analysis of the clinicopathogical parameters for overall survival and progression free survivalOverall survivalProgression free survivalHR95% CI*P*HR95% CI*P*FIGO stage (early stage vs. advanced stage)1.1270.357--3.5620.8381.7440.576--5.2880.325Histologic grade (well vs. poor and moderate)0.6150.256--1.4750.2760.9040.393--2.0770.811Ascites (no vs. yes)0.8500.381--1.8970.6920.6670.337--1.3230.247LN metastasis (no vs. yes)0.9240.460--1.8560.8230.7860.410--1.5060.468Age (≤50 vs. \>50 years)2.9201.466--5.8150.0022.4031.302--4.4350.005Preoperative CA125 (U/ml) (≤600 vs. \>600)0.5480.280--1.0730.0790.3270.177--0.6070.000DOT1L expression (low vs. high)4.7052.160--10.2480.0008.8843.974--19.8610.000*HR* hazard ratio, *CI* confidence interval

Knocking down of DOT1L inhibits the proliferation of ovarian cancer cells and induces G1 phase arrest {#Sec18}
-----------------------------------------------------------------------------------------------------

Given the fact that DOT1L has strong correlation with malignant behavior of ovarian cancer, such as late FIGO stage and poor histologic grade, a loss-of-function approach was applied to explore the function of DOT1L. First, we detected the expression levels of DOT1L in various OC cell lines by Western blot (Fig. [2a](#Fig2){ref-type="fig"}). SK-OV-3 and TOV21G cells have a relatively high expression of DOT1L compared with the other cell lines; therefore, we chose these two cell lines to knock down DOT1L. Successful knockdown by shDOT1L shRNA lentiviral particles was verified by RT-PCR (Fig. [2b](#Fig2){ref-type="fig"}) and Western blot (Fig. [2c](#Fig2){ref-type="fig"}). It was worth to note that the level of H3K79me2 was reduced responding to knockdown of DOT1L protein expression. To determine if knock-down of DOT1L expression by shRNA could lead to a decrease in the proliferation and survival of OC cells, CCK8 and colony formation assay were performed. The OD450 values of the SK-OV-3 and TOV21G cells transfected with shDOT1L shRNAs lentiviral particles showed significant decrease (all *P* \< 0.05), compared with those cells in the control groups (Fig. [2d](#Fig2){ref-type="fig"}). The colony formations of transfected SK-OV-3 and TOV21G cells were also significantly reduced compared with the control groups (all *P* \< 0.05, Fig. [2e](#Fig2){ref-type="fig"}). Consistent with knock-down of DOT1L expression genetically using shRNA, the proliferation and survival of OC cells were also reduced by inhibition of DOT1L enzymatic activity pharmacologically with EPZ004777 and SGC0946 treatment (Fig. [2f and g](#Fig2){ref-type="fig"}). SGC0946 was capable of inhibiting the growth of both SK-OV-3 and TOV21G cells in a dose- and time-dependent manner (Fig. [2f](#Fig2){ref-type="fig"}). Both EPZ004777 and SGC0946 could reduce the colony formation rate of SK-OV-3 and TOV21G cells (Fig. [2g](#Fig2){ref-type="fig"}). In order to evaluate the therapeutic effects of DOT1L inhibitors on a larger ovarian cancer cell line panel in vitro, we chose OV90 and CaOV3, which could represent high-grade serous ovarian cancer for CCK8 and colony formation assay \[[@CR33]\]. Intriguingly, SGC0946 was capable of inhibiting the growth of both OV90 and CaOV3 cells in a dose- and time-dependent manner (Additional file [2](#MOESM2){ref-type="media"}: Figure S1c). Both EPZ004777 and SGC0946 could reduce the colony formation rate of OV90 and CaOV3 cells (Additional file [2](#MOESM2){ref-type="media"}: Figure S1d).Fig. 2Knocking down of DOT1L inhibits the proliferation of ovarian cancer cells. **a** Western blot analysis of DOT1L expression in various ovarian cancer cell lines. GAPDH was used as loading control. **b** RT-PCR analysis of endogenous DOT1L mRNA expression in SK-OV-3 and TOV21G cells that were transfected with shRNAs lentiviral articles against DOT1L as indicated in the figure. The shRNAs were able to knockdown DOT1L. **c** Western blot analysis of SK-OV-3 and TOV21G cells transfected with shDOT1L shRNAs. The blot was probed with DOT1L and H3K79me2 antibodies. GAPDH and H3 were used as loading control. **d** The cell proliferation of SK-OV-3 and TOV21G was determined by CCK-8 assay after shDOT1L shRNAs transfection (*n* = 3). The results are representative of three independent experiments. *P* \< 0.05. **e** The colony formation assay was performed in SK-OV-3 and TOV21G cells after shDOT1L shRNAs transfection (*n* = 3). Representative images (*left*) and the histogram (*right*) of three independent experiments were shown. *P* \< 0.05. **f** SK-OV-3 and TOV21G cells were seeded in 96-well plates and cultured in the presence of SGC0946 at variable concentrations (0, 0.2, 2, or 20 μM) for up to 12 days. Then, the OD450 values of corresponding cells were measured at 0, 3, 6, 9, and 12 days after SGC0946 treatment. The results are representative of three independent experiments. (*n* = 3, *P* \< 0.05). **g** The colony formation assay was performed in SK-OV-3 and TOV21G cells after 10 μM EPZ004777 and 10 μM SGC0946 treatment for up to 12 days. Representative images (*left*) and the histogram (*right*) of three independent experiments were shown. (*n* = 3, *P* \< 0.05)

To further determine the reason that knockdown DOT1L inhibits ovarian cancer cell proliferation, we next performed flow cytometric analysis of apoptosis and cell cycle. None effect of DOT1L on apoptosis of either SK-OV-3 or TOV21G cells was seen after treatment with EPZ004777 and SGC0946 for up to 12 days (Fig. [3a, b](#Fig3){ref-type="fig"}). However, EPZ004777 and SGC0946 treatment induced increased G1 population and decreased S phase and G2/M phase cells in asynchronized SK-OV-3 and TOV21G cells (Fig. [3c, d](#Fig3){ref-type="fig"}, Additional file [4](#MOESM4){ref-type="media"}: Figure S2). Similar result was seen in both SK-OV-3 and TOV21G cells transfected with DOT1L shRNA lentivirus (GeneChem) (Additional file [5](#MOESM5){ref-type="media"}: Figure S3). These results demonstrate that blocking DOT1L in ovarian cancer could result in G1 arrest and thereby impede the cell proliferation in vitro*.* Fig. 3Effect of blocking DOT1L in the cell apoptosis and cell cycle. After exposure to 10 μM EPZ004777 and SGC0946 seperately for 12 days in both SK-OV-3 and TOV21G cells, cell apoptosis and cell cycle analyses in each group were determined by flow cytometry. **a** The typical images and **b** the proportion of apoptosis cell were measured in SK-OV-3 and TOV21G cells. The proportion of cell cycle distribution in SK-OV-3 cells (**c**) and in TOV21G cells (**d**) was shown. *Columns* are the mean of triplicate samples

DOT1L regulates the transcription of G1 arrest genes CDK6 and CCND3 through H3K79 dimethylation {#Sec19}
-----------------------------------------------------------------------------------------------

Given that knocking down of DOT1L could inhibit the proliferation of ovarian cancer cells in vitro and induce G1 arrest as mentioned above, we then proceeded to elucidate the molecular mechanism underlying this phenomenon. To identify genes regulated by DOT1L in ovarian cancer cells, we performed chromatin immune-precipitation coupled with high-throughput sequencing (ChIP-seq) analysis using ChIP-grade DOT1L antibody in SK-OV-3 cells. The proportion of DOT1L peaks was 8.60% distributed in promoters, 3.20% in exons, 39.60% in introns, and 48.6% in intergenics (Fig. [4a](#Fig4){ref-type="fig"}). The average distribution of DOT1L-bound peaks near TSS was shown in Fig. [4b](#Fig4){ref-type="fig"}. We then examined the change of expression in mRNA level of primary genes involved in G1 arrest responding to knocking down of DOT1L in OC cells. These primary G1 arrest genes include D-type cyclins (D1, D2, and D3), cyclin E, and Cdks (2, 4, and 6) \[[@CR29], [@CR30]\]. Downregulation of CCND3 and CDK6 were seen in SK-OV-3 cells and TOV21G cells both by DOT1L shRNAs silicing and treated with DOT1L inhibitors (Fig. [4c, d](#Fig4){ref-type="fig"}, Additional file [6](#MOESM6){ref-type="media"}: Figure S4a and b). However, we could not detect the change of other G1 arrest genes. Interestingly, among these downregulated genes responding to DOT1L-knockdown, we found the intron of CDK6 and CCND3 genes were bound to DOT1L, suggesting that CDK6 and CCND3 genes were the direct target genes of DOT1L (Additional file [7](#MOESM7){ref-type="media"}). To verify whether DOT1L directly regulated the transcription of CDK6 and CCND3 through the H3K79 dimethylation, we performed ChIP-PCR using ChIP-grade antibodies for DOT1L and H3K79me2, targeting the detected binding sites nearby with three different primer sets. In accordance with the results above, CDK6 levels in DOT1L-immunoprecipitants were decreased by more than 12 times in the shDOT1L transfected SK-OV-3 cells compared with the control (*P* \< 0.0001, Student's *t* test), and an approximately 5-fold decrease of CDK6 was observed in the H3K79me2-enriched cell lysates (*P* \< 0.0001, Student's *t* test) (Fig. [4e](#Fig4){ref-type="fig"}). Likewise, we observed a decrease in the CCND3 levels by near 13 times in the DOT1L-immunoprecipitants of the lysates from shDOT1L transfected SK-OV-3 cells (*P* \< 0.0001, Student's *t* test), and by more than 4 times decrease in the H3K79me2-immunoprecipitants (*P* \< 0.0001, Student's *t* test) (Fig. [4f](#Fig4){ref-type="fig"}).Similar results were seen in TOV21G cells (Additional file [6](#MOESM6){ref-type="media"}: Figure S4). We further confirmed downregulation of CDK6 and cyclin D3 in both SK-OV-3 and TOV21G cells knockdown of DOT1L at the protein level, which are critical for normal G1 phase progression \[[@CR34], [@CR35]\] (Fig. [5](#Fig5){ref-type="fig"}). These results support that blocking DOT1L can result in G1 arrest through its H3K79 dimethylation activity.Fig. 4DOT1L regulates the transcription of G1 arrest genes CDK6 and CCND3 through H3K79 dimethylation. **a** Genomic distribution of DOT1L ChIP-seq peaks in SK-OV-3 cells. The proportion of DOT1L peaks was 8.60% distributed in promoters, 3.20% in exons, 39.60% in introns, and 48.6% in intergenics. **b** The average distribution of DOT1L-bound peaks near TSS. **c** and **d** RT-PCR detecting the change of primary G1 arrest genes, D-type cyclins (D1, D2, and D3), cyclin E, Cdks (2, 4, and 6) in mRNA levels in SK-OV-3 cells knocking down of DOT1L with shDOT1L shRNAs lentiviral particles (**c**) and DOT1L inhibitors, EPZ004777 and SGC0946 (**d**) (*P* \< 0.05, Student's *t* test, data represented as mean±SD). **e** and **f** DOT1L transcriptionally regulates the expression of CDK6 (**e**) and CCND3 (**f**) through induction of H3K79 dimethylation in the binding regions of these genes. Chromatin immunoprecipitation (ChIP) PCR assays were performed in a loss-of-function system. SK-OV-3 cells were transfected with shDOT1L shRNAs and shCON lentiviral particles and ChIP assays using anti-DOT1L and anti-H3K79me2 antibodies were performed with ChIP primers targeting the binding regions of CDK6 and CCND3 (*P* \< 0.05, Student's *t* test, data represented as mean±SD) Fig. 5Knocking down of DOT1L decreases the expression of CDK6 and cyclin D3 in ovarian cancer cells. Western blotting confirmed decrease of corresponding G1 arrest proteins, CDK6, and cyclin D3 protein levels in SK-OV-3 cells and TOV21G cells knocking down of DOT1L with shDOT1L shRNAs (**a**) and DOT1L inhibitor, SGC0946 (**b**). **c** and **d** Densitometric analysis of the Western blot. Data shown are mean±SD and a two-tailed Mann-Whitney test was used for statistical analysis (*P* \< 0.05). GAPDH or H3 was loading as control

Effect of inhibition of DOT1L pharmacologically on tumor progression in vivo {#Sec20}
----------------------------------------------------------------------------

To determine whether DOT1L has a functional role in tumor progression in vivo, we used a mouse orthotopic xenograft ovarian cancer model. Mice treated with SGC0946 displayed obviously slower progress in tumor growth compared with the mice untreated (Fig. [6a](#Fig6){ref-type="fig"}). After the sacrifice of these mice, tumor masses were removed and weighted. The size and weight of tumor masses treated with SGC0946 were significantly smaller than the untreated group (Fig. [6b](#Fig6){ref-type="fig"}). We performed RT-PCR analysis for CDK6 and CCND3 on these tumor masses. CDK6, as well as CCND3, was significantly decreased in SGC0946-treated group than the untreated group (Fig. [6c, d](#Fig6){ref-type="fig"}). Representative IHC images for H3K79me2, CDK6, and cyclin D3 in the mice were shown to confirm the inhibition of DOT1L enzymatic activity upon SGC0946 treatment, showing impeded H3K79me2, CDK6, and cyclin D3 levels in the tumors (Fig. [6e, f](#Fig6){ref-type="fig"}). Taken together, these results demonstrated that DOT1L inhibitors could inhibit tumor growth in vivo.Fig. 6Effect of inhibition of DOT1L pharmacologically on tumor progression in vivo. After orthotopic transplantation of tumors performed by SK-OV-3 cells transduced with CMV-Fluc-IRES-RFP lentiviral particles, BALB/c-nude mice were treated with SGC0946 (10 mg/kg body weight) or vehicle control twice a week for 6 weeks by intraperitoneal injection. The size of tumor was closely monitored by three-dimensional reconstruction of in vivo bioluminescence images. **a** The representative images (*left*) were shown and tumor size (*right*) was calculated (*n* = 9 per group, *P* \< 0.05, Student's *t* test, data represented as mean±SD). **b** The mice were sacrificed after being monitored using the IVIS SPECTRUM system. Photograph of tumor masses (*left*) was shown and the tumor weight (*right*) was measured (*n* = 9 per group, *P* \< 0.05, Student's *t* test, data represented as mean±SD). RT-PCR was performed on the tumor masses from the mice mentioned above to analyze the expression of CDK6 (**c**) and CCND3 (**d**). GAPDH was used as a loading control. **e** Representative IHC images for H3K79me2, CDK6, and cyclin D3 in the mice were shown. **f** The positive cells of H3K79me2, CDK6, and cyclin D3 were measured

Discussion {#Sec21}
==========

This is the first study to examine DOT1L expression and H3K79 methylation in ovarian cancer. In human, DOT1L is involved in the oncogenesis of several leukemia subtypes, mostly characterized by chromosomal translocations involving the mixed lineage leukemia (MLL) gene \[[@CR36]\]. To identify the role of DOT1L in ovarian cancer, we performed immunohistochemistry and found that DOT1L expression was significantly increased in malignant ovarian cancer. In addition, H3K79 methylation was also significantly increased in malignant ovarian cancer, indicating the correlation of DOT1L and H3K79 methylation in ovarian cancer. Higher DOT1L expression was associated with advanced FIGO stage, poor histopathological grade, and lymph node metastasis of OC patients. Importantly, DOT1L expression was identified as an independent prognostic factor for OC, which raised the possibility that DOT1L might be correlated with malignant behavior of ovarian cancer. As expected, our in vitro experiment demonstrated that blocking DOT1L in ovarian cancer could lead to the decrease of ovarian cancer cell viability and colony-forming ability.

DOT1L has a critical role in regulating gene transcription, development, cell cycle progression, somatic reprogramming, and DNA damage repair \[[@CR37]--[@CR39]\]. Consistent with previous finding that DOT1L siRNA-transfected human lung cancer cells undergo G1 cell cycle arrest \[[@CR40]\], we showed here that knocking down of DOT1L in ovarian cancer cells could result in G1 arrest and therefore impede the cell proliferation. It is worth mentioning that asynchronized cells were used for cell cycle analysis in this paper, due to the reason that DOT1L might be related with DNA replication \[[@CR38], [@CR39]\]. Most importantly, the present study provides mechanistic insight into the inhibition of ovarian cancer cell proliferation by blocking DOT1L via downregulation of CDK6 and CCND3 through H3K79 dimethylation, providing a novel mechanism of epigenetic regulation of DOT1L-mediated transcription of cell cycle genes. The D-type cyclins (cyclins D1, D2, and D3) are the first cyclins to be induced as cells enter the G1 phase of the cell cycle \[[@CR34], [@CR41], [@CR42]\]. D-type cyclins associate with and activate cyclin-dependent kinases (CDK), such as CDK4 and CDK6 \[[@CR34]\]. Specially, cyclin D3 was identified as a direct target of Notch1 that promotes cell-cycle progression and proliferation both in peripheral and leukemic T cells \[[@CR43]\]. The data presented in this report demonstrated that DOT1L regulation of cell cycle was through CDK6 and CCND3. Although several studies reported that some histone modifications transcriptionally regulated the expression of cell cycle regulators such as CDK inhibitors to govern cell cycle progression \[[@CR40], [@CR44], [@CR45]\], in fact, our data together with the described molecular functions identified CDK6 and cyclin D3 as transcriptionally regulated genes by DOT1L. Given the fact that the cell-cycle arrest network is complex, because the regulators involved act redundantly, have multiple substrates, and provide feedback control \[[@CR46]\], the phenomenon was explainable.

The dynamic interplays among different chromatin post-transcription modifications control gene expression and provide novel opportunities for targeted combination therapies in multiple cancer types. Molecular targeting of specific histone methyltransferase is emerging as a new direction for cancer therapy \[[@CR47]\]. Of the known histone methyltransferase enzymes, DOT1L is a promising target due to it being the only known H3K79 histone methyltransferase, its unique non-SET catalytic domain, and its role in promoting and maintaining MLL leukemogenesis \[[@CR48], [@CR49]\]. It is interesting to note that small molecule DOT1L inhibitors have been recently developed, and one of the DOT1L inhibitors is already under investigation in a phase I clinical trial in patients with MLL fusion gene-driven leukemia \[[@CR37]\]. Fortunately, our data showed that inhibition of DOT1L enzymatic activity with EPZ004777 and SGC0946 treatment could suppress ovarian cancer cell proliferation in vitro, and furthermore, administration of SGC0946 in vivo resulted in significant inhibition of tumor progression in the ovarian orthotopic xenograft mice model. Consequently, DOT1L could have strong prospects for therapeutic target in ovarian cancer.

Conclusions {#Sec22}
===========

Our findings first demonstrated that OC patients expressing high level of DOT1L have poorer OS and PFS compared with those with low DOT1L expression, and DOT1L expression can be regarded as an independent prognostic factor. Furthermore, DOT1L regulates the transcription of G1 phase genes CDK6 and CCND3 through H3K79 dimethylation, thereby knocking down of DOT1L could result in G1 arrest and therefore impede the cell proliferation and tumor progression both in vitro and in vivo. Our results suggest that DOT1L might be potential target for prognostic assessment and therapeutic intervention in ovarian cancer.
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Additional file 1: Table S1.The primer sequences used for PCR. (DOCX 15 kb) Additional file 2: Figure S1.Immunostaining of H3K79 methylation in human ovarian cancer specimens and effects of DOT1L inhibitors in vitro*.* (a) Immunohistochemical staining of H3K79 methylation in human ovarian tissues. A brown color in cancer cells is considered as a positive staining. Negative control without first antibody is performed in the normal ovarian tissue. Representative images of H3K79 methylation in normal ovarian tissues and benign, borderline, and malignant ovarian tumors are shown. Original magnification ×100 and ×400. Scale bar 100 μm and 25 μm, respectively. (b) The case rate of H3K79 methylation high and low expression. For comparison between two groups, *χ* ^2^ test was applied. (c) OV90 and CaOV3 cells were seeded in 96-well plates and cultured in the presence of SGC0946 at variable concentrations (0, 0.2, 2, or 20 μM) for up to 12 days. Then the OD450 values of corresponding cells were measured at 0, 3, 6, 9, and 12 days after SGC0946 treatment. The results are representative of three independent experiments. (*n* = 3, *P* \< 0.05). (d) The colony formation assay was performed in OV90 and CaOV3 cells after 10 μM EPZ004777 and 10 μM SGC0946 treatment for up to 12 days. The histogram of three independent experiments was shown. (*n* = 3, *P* \< 0.05). (TIF 5990 kb) Additional file 3: Table S2.Univariate Cox regression analysis of the clinicopathogical parameters for overall survival and progression free survival. (DOCX 17 kb) Additional file 4: Figure S2.Effect of blocking DOT1L in cell cycle. After exposure to 10 μM EPZ004777 and SGC0946 seperately for 12 days in both SK-OV-3 and TOV21G cells, cell apoptosis and cell cycle analyses in each group were determined by flow cytometry. The typical images of cell cycle in SK-OV-3 cells (a) and in TOV21G cells (b) were shown. (TIF 713 kb) Additional file 5: Figure S3.Effect of blocking DOT1L using shRNAs in the cell apoptosis and cell cycle. ShDOT1L-1 and shDOT1L-2 shRNA lentiviral particles (GeneChem) were used to knock-down DOT1L expression in both SK-OV-3 and TOV21G cells, cell apoptosis and cell cycle analyses in each group were determined by flow cytometry. (a) The typical images and (b) the proportion of apoptosis cell were measured in SK-OV-3 and TOV21G cells. The typical images (c) and the proportion of cell cycle distribution (d) in SK-OV-3 cells were shown. The typical images (e) and the proportion of cell cycle distribution (f) in TOV21G cells were shown. Columns are the mean of triplicate samples. (TIF 1351 kb) Additional file 6: Figure S4.DOT1L regulates the transcription of G1 arrest genes CDK6 and CCND3 through H3K79 dimethylation. (a) and (b) RT-PCR detecting the change of primary G1 arrest genes, D-type cyclins (D1, D2, and D3), cyclin E, Cdks (2, 4, and 6) in mRNA levels in TOV21G cells knocking down of DOT1L with shDOT1L shRNAs lentiviral particles (a) and DOT1L inhibitors, EPZ004777 and SGC0946 (b) (*P* \< 0.05, Student's *t* test, data represented as mean±SD). (c) and (d) DOT1L transcriptionally regulates the expression of CDK6 (c) and CCND3 (d) through induction of H3K79 dimethylation in the binding regions of these genes. Chromatin immunoprecipitation (ChIP) PCR assays were performed in a loss-of-function system. TOV21G cells were transfected with shDOT1L shRNAs and shCON lentiviral particles, and ChIP assays using anti-DOT1L and anti-H3K79me2 antibodies were performed with ChIP primers targeting the binding regions of CDK6 and CCND3 (*P* \< 0.05, Student's *t* test, data represented as mean±SD). (TIF 815 kb) Additional file 7:Possible target genes of DOT1L analyzed from DOT1L ChIP-seq. (XLSX 854 kb)
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